Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1512)	3/6/2000 8:43:00 PM
From: michael_f_murphy	Respond to of 4974

<<Then someone else can take the idea to another thread, if it proves to be useful.>> This would seem to be a natural home unless RWR objects: Subject 32089

To: scaram(o)uche who wrote (1512)	3/7/2000 9:18:00 AM
From: scaram(o)uche	Respond to of 4974

biz.yahoo.com (snip) "It's the Celera effect," says Stefan Loran, analyst with Legg Mason Wood Walker in Baltimore who has no formal rating on the stock. "Everyone and [his] brother is trying to go public." "There's a real frenzy to raise money," adds Glyn O. Edwards, chief executive of Antisoma , a British biotechnology company that listed on the London Stock Exchange last year. "They are trying to raise as much as they can to ride them out through the rest of the cycle." (snip) It's so darn easy to call it the CRA effect. Whatever, it's here. <g>

To: scaram(o)uche who wrote (1512)	3/7/2000 9:18:00 AM
From: rexnine	Read Replies (5) \| Respond to of 4974

MABA might get a pop this morning on news it is making available its patented enabling technology -- the antigen-free mouse colony -- to pharmaceutical and biotechnology companies who wish to utilize it for Mab production. MABA has had a nice run from $0.75 last month.